A study of TRAIL receptors in squamous cell carcinoma of the head and neck

Archives of Otolaryngology - Head and Neck Surgery

Volumn 131, Issue 5, 2005, Pages 407-412

  Teng, Marita S ^a   Brandwein Gensler, Margaret S ^b   Teixeira, Miriam S ^c   Martignetti, John A ^c   Duffey, Dianne C ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; GENOMIC DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; DISEASE COURSE; DISEASE PREDISPOSITION; DNA ISOLATION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; POLYMORPHONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC CELL GENETICS; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DNA, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18344388721     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.131.5.407     Document Type: Article

References (27)

1. Chin D, Boyle GM, Theile DR, et al. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg. 2004;57:595-602.
2. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med. 1995;332:712-717.
3. Liu X, Yue P, Khuri FR, Sun SY. p53 Upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004;64:5078-5083.
4. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002;7:449-459.
5. Pan G, Hi J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815-818.
6. Hu WH, Johnson H, Shu HB. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NFkB and JNK activation and apoptosis through distinct pathways. J Biol Chem. 1999;274:30603-30610.
7. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.
8. Fisher MJ, Virmani AK, Wu L, et al. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 2001;7:1688-1697.
9. Pai SI, Wu GS, Ozoren N, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 1998;58:3513-3518.
10. Lee SH, Shin MS, Kim HS, et al. Alterations of the DB5/TRAIL receptor 2 gene in non-small cell lung cancer. Cancer Res. 1999;59:5683-5686.
11. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308.
12. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
13. Kim JH, Ajaz M, Lokshin A, et al. Role of antiapoptosis proteins in TRAIL and cisplatin-augmented apoptosis. Clin Cancer Res. 2003;9:3134-3141.
14. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8:2553-2562.
15. Secchiero P, Gonelli A, Ciabattoni G, et al. TNF-related apoptosis-inducing ligand (TRAIL) up-regulated cyclooxygenase (COX)-1 activity and PGE2 production in cells of the myeloid lineage. J Leukoc Biol. 2002;72:986-994.
16. Secchiero P, Gonelli A, Mirandola P, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood. 2002;100:2421-2429.
17. Renshaw SA, Parmar JS, Singleton V, et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol. 2003;170:1027-1033.
18. Whiteside T. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol. 2002;12:43-50.
19. Sheikh MS, Hunga Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 1999;18:4153-4159.
20. Meng RD, McDonald ER, Sheikh MS, Fornace AJ, El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, pte-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 2000;1:130-144.
21. Ivanov V, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene. 2003;22:3152-3161.
22. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:2221-2232.
23. Xu L, Pirollo KF, Tang WH, et al. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10:2941-2952.
24. Clayman GL, Frank DK, Bruso PA, et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 1999;5:1715-1722.
25. Frank DK, Frederick MJ, Liu TJ, et al. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res. 1998;4:2521-2528.
26. Guan B, Yue P, Clayman GL, et al. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol. 2001;188:98-105.
27. Jang SH, Seol JY, Kim CH, et al. Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines. Int J Mol Med. 2004;13:181-186.